RedHill Biopharma Ltd. (RDHL)
NASDAQ: RDHL · Real-Time Price · USD
1.820
0.00 (0.00%)
Jun 27, 2025, 4:00 PM - Market closed
RedHill Biopharma Revenue
In the year 2024, RedHill Biopharma had annual revenue of $8.04M with 23.17% growth. RedHill Biopharma had revenue of $5.47M in the half year ending December 31, 2024, a decrease of -81.97%.
Revenue (ttm)
$8.04M
Revenue Growth
+23.17%
P/S Ratio
0.28
Revenue / Employee
$229,800
Employees
35
Market Cap
4.17M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.04M | 1.51M | 23.17% |
| Dec 31, 2023 | 6.53M | -55.27M | -89.43% |
| Dec 31, 2022 | 61.80M | -23.96M | -27.94% |
| Dec 31, 2021 | 85.76M | 21.40M | 33.25% |
| Dec 31, 2020 | 64.36M | 58.07M | 923.03% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
RDHL News
- 6 weeks ago - RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win - PRNewsWire
- 2 months ago - RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress - PRNewsWire
- 2 months ago - RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107 - PRNewsWire
- 2 months ago - RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency - PRNewsWire
- 2 months ago - RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption - PRNewsWire
- 2 months ago - RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights - PRNewsWire
- 3 months ago - RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation - PRNewsWire
- 3 months ago - RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results - PRNewsWire